Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia

Summary

The purpose of this study is to find out what effects a new drug, buparlisib, has on chronic lymphocytic leukemia.

Timeline

Start

2015-04-27

Primary completion

2018-11-21

Completion

2020-04-28

Publications

• Results Assouline S, Amrein L, Aloyz R, Banerji V, Caplan S, Owen C, Hasegawa W, Robinson S, Shivakumar S, Prica A, Peters A, Hagerman L, Rodriguez L, Skamene T, Panasci L, Chen BE, Hay AE. IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leuk Lymphoma. 2020 Jul;61(7):1653-1659. doi: 10.1080/10428194.2020.1734594. Epub 2020 Mar 10.

Drugs

Indications